Elite in Pseudomyxoma Peritonei

Olivier J. Glehen

Lyon, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Elite in Pseudomyxoma Peritonei
Lyon, FR 
OverviewLocationsClinical Research

Overview

Olivier Glehen practices in Lyon, France. Mr. Glehen is rated as an Elite expert by MediFind in the treatment of Pseudomyxoma Peritonei. His top areas of expertise are Pseudomyxoma Peritonei, Ovarian Cancer, Mesothelioma, Hepato-Pancreato-Biliary Surgery, and Ileostomy.

His clinical research consists of co-authoring 348 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 32 articles in the study of Pseudomyxoma Peritonei.

Gender
Male

Locations

Lyon, France
Other Locations
Oullins, 69395, France
Pierre-la-treiche, France
Auvergny, France
Aix Marseille Univ, APHM, CHU Timone
Marseille, France
Villeurbanne, France
Chemin-d'aisey, 69495, France
AP HP, CHU Henri Mondor
Creteil, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Phase III Randomized Clinical Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer Considering Two Different Settings: Primary Debulking Surgery (PDS) and Interval Debulking Surgery (IDS)
Phase III Randomized Clinical Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer Considering Two Different Settings: Primary Debulking Surgery (PDS) and Interval Debulking Surgery (IDS)
Enrollment Status: Recruiting
Publish Date: September 22, 2025
Intervention Type: Drug
Study Drug: HIPEC
Study Phase: Phase 3
A Phase III Randomized Study Evaluating Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in the Treatment of Relapse Ovarian Cancer
A Phase III Randomized Study Evaluating Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in the Treatment of Relapse Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 23, 2025
Intervention Type: Procedure, Drug
Study Drug: Hyperthermic Intra-PEritoneal Chemotherapy
Study Phase: Phase 3
GASTRICHIP : D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma. A Randomized and Multicentric Phase III Study.
GASTRICHIP : D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma. A Randomized and Multicentric Phase III Study.
Enrollment Status: Active_not_recruiting
Publish Date: May 08, 2024
Intervention Type: Procedure, Drug
Study Drug: HIPEC with oxaliplatin
Study Phase: Phase 3
Clinical and Biological Digestive Peritoneal Carcinomatosis Data Base From the French National Network of Peritoneal Surface Malignancies
Clinical and Biological Digestive Peritoneal Carcinomatosis Data Base From the French National Network of Peritoneal Surface Malignancies
Enrollment Status: Completed
Publish Date: December 22, 2023
Intervention Type: Other
Study Phase: Not Applicable
Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment : Phase II Multicentric Randomized Double Bland Placebo Controlled Study
Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment : Phase II Multicentric Randomized Double Bland Placebo Controlled Study
Enrollment Status: Completed
Publish Date: April 04, 2022
Intervention Type: Drug
Study Drug: Pasireotide
Study Phase: Phase 2
View 4 Less Clinical Trials

348 Total Publications

ASO Visual Abstract: Preoperative Peritoneal MRI: Usefulness to Highlight Potential Hidden Lesions for Complete Cytoreductive Surgery in Colorectal Cancer Patients with Surgical History.
ASO Visual Abstract: Preoperative Peritoneal MRI: Usefulness to Highlight Potential Hidden Lesions for Complete Cytoreductive Surgery in Colorectal Cancer Patients with Surgical History.
Journal: Annals of surgical oncology
Published: September 09, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Glehen's expertise for a condition
ConditionClose
View All 30 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile